|
Real-time Estimate
Cboe BZX
09:48:00 2026-09-30 EDT
|
5-day change | 1st Jan Change | ||
| 0.8580 USD | -1.55% |
|
+0.15% | -43.11% |
| 09-18 | Maxim Initiates MIRA Pharmaceuticals at Buy With $3.50 Price Target | MT |
| 09-17 | MIRA Pharmaceuticals, Inc. Advances Ketamir-2 To Phase 2a In Chemotherapy-Induced Peripheral Neuropathy | CI |
| Market Cap | 36.62M 32.32M 30.58M 27.73M 51.99M 3.51B 52.51M 367M 141M 1.79B 138M 135M 5.77B | P/E 2026 * |
-7.26x | P/E 2027 * | -5.45x |
|---|---|---|---|---|---|
| Enterprise Value | 36.62M 32.32M 30.58M 27.73M 51.99M 3.51B 52.51M 367M 141M 1.79B 138M 135M 5.77B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
69.42% | Yield 2026 * |
-
| Yield 2027 * | - |
NasdaqUSD
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| MIRA | Delayed | |
CBOE
| MIRA | Real-time | |
|
Deutsche Boerse AG
| K6S | Delayed | |
|
Deutsche Boerse AG
| K6S | End-of-day quote | |
|
Tradegate
| K6S | Real-time | |
|
Börse Stuttgart
| K6S | Delayed | |
|
Boerse Muenchen
| K6S | Real-time |
| 1 day | -1.55% | ||
| 1 week | +0.15% | ||
| Current month | +11.53% | ||
| 1 month | +11.53% | ||
| 3 months | -9.24% | ||
| 6 months | -10.83% | ||
| Current year | -43.11% |
| 1 week | 0.83 |  | 0.91 |
| 1 month | 0.71 | | 1.1 |
| Current year | 0.6 | | 1.54 |
| 1 year | 0.6 | | 2.45 |
| 3 years | 0.51 | | 6.4 |
| 5 years | 0.51 | | 7.98 |
| 10 years | 0.51 | | 7.98 |
| Manager | Title | Age | Since |
|---|---|---|---|
Erez Aminov
CEO | Chief Executive Officer | 48 | 2023-03-31 |
Andriy Mushak
DFI | Director of Finance/CFO | 43 | 2026-06-05 |
| Director | Title | Age | Since |
|---|---|---|---|
Erez Aminov
CHM | Chairman | 48 | 2024-03-12 |
| Director/Board Member | 44 | 2024-03-12 | |
Denil Shekhat
BRD | Director/Board Member | 45 | 2024-03-12 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 3/30/26 | Free | Chief Executive Officer | 83,500 | 0.1994% | ||
| 12/31/25 | Free | Chief Executive Officer | 5,120,955 | 12.2288% | ||
| 10/1/25 | Free | Chief Executive Officer | 2,685,456 | 16.2157% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.55% | +0.15% | -36.84% | -81.61% | 36.62M | |
| -0.70% | -4.28% | +52.62% | +86.42% | 71.53B | |
| -0.83% | +0.65% | +36.29% | +80.13% | 60.12B | |
| -1.23% | +2.85% | +9.60% | +37.41% | 48.85B | |
| +0.49% | +0.76% | +42.10% | +39.21% | 44.28B | |
| +0.10% | +6.84% | +336.36% | +678.68% | 43.83B | |
| +1.99% | +3.02% | +10.37% | +110.67% | 41.53B | |
| +0.34% | +0.22% | +5.18% | +47.36% | 30.13B | |
| +4.77% | +6.16% | +36.77% | +26.10% | 27.98B | |
| -1.31% | -3.58% | -20.77% | +349.74% | 25.25B | |
| Average | +0.17% | -0.44% | +47.17% | +137.41% | 39.35B | |
| Weighted average by Cap. | +0.11% | -0.16% | +61.27% | +152.18% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -4.94M -4.36M -4.13M -3.74M -7.02M -474M -7.09M -49.5M -19.08M -242M -18.56M -18.15M -779M | -7.35M -6.49M -6.14M -5.57M -10.44M -706M -10.54M -73.65M -28.39M -360M -27.61M -27.01M -1.16B |
| Net Debt | - | - |
Employees
-
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-30 | US$0.8590 | -1.43% | 829 |
| 26-09-29 | US$0.8715 | -3.52% | 63,225 |
| 26-09-28 | US$0.9033 | +0.37% | 65,818 |
| 26-09-25 | US$0.9000 | +7.21% | 95,119 |
| 26-09-24 | US$0.8395 | -2.12% | 54,094 |
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.8715USD
Average target price
3.500USD
Spread / Average Target
+301.61%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- MIRA Stock
Select your edition
All financial news and data tailored to specific country editions
